GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Additional Paid-In Capital

REGMF (RemeGen Co) Additional Paid-In Capital : $846.5 Mil(As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Additional Paid-In Capital?


RemeGen Co's quarterly additional paid-in capital declined from Dec. 2023 ($862.8 Mil) to Jun. 2024 ($849.6 Mil) but then stayed the same from Jun. 2024 ($849.6 Mil) to Dec. 2024 ($846.5 Mil).

RemeGen Co's annual additional paid-in capital declined from Dec. 2022 ($883.7 Mil) to Dec. 2023 ($862.8 Mil) and declined from Dec. 2023 ($862.8 Mil) to Dec. 2024 ($846.5 Mil).


RemeGen Co Additional Paid-In Capital Historical Data

The historical data trend for RemeGen Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Additional Paid-In Capital Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial - - 883.70 862.84 846.53

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 883.70 860.29 862.84 849.56 846.53

RemeGen Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

RemeGen Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

From GuruFocus

RemeGen Celebrates World Intellectual Property Day 2023

By PRNewswire PRNewswire 04-26-2023